Profluent and Eli Lilly have entered a significant multi-program collaboration valued at up to $2.25 billion, focusing on advanced AI-driven genetic medicine aimed at precision DNA editing.
The partnership centers around Profluent's innovative use of AI to develop recombinases, which are enzymes designed for kilobase-scale DNA editing. This technology is particularly important for addressing genetic diseases characterized by multiple mutations, a challenge that traditional methods like CRISPR struggle to overcome. According to Profluent's CEO, Ali Madani, this capability represents a “holy grail” in the field of gene therapy.
Eli Lilly will have exclusive rights to further develop and commercialize selected therapeutic targets derived from this collaboration, which includes various forms of upfront payments, research funding, and milestone royalties. This agreement is a continuation of Lilly's strategic investment in AI for genetic medicine, emphasizing their commitment to tackling complex genetic disorders that require more than single edits.
This partnership highlights the transformative potential of AI in gene editing, suggesting it could pave the way for new therapies that address significant unmet medical needs. As both companies push the boundaries of genetic medicine, the implications for patient care and treatment methodologies could be profound.